BIO-BHIGH SIGNALFINANCIAL10-K

Bio-Rad experienced a dramatic decline in operating income while maintaining healthy cash generation and balance sheet growth.

The steep drop in operating profitability despite growing assets and cash flow suggests significant one-time charges, restructuring costs, or margin compression that requires immediate investor attention. The company's ability to generate strong operating cash flow and continue aggressive share repurchases indicates underlying business resilience, but the operating income collapse demands explanation.

Comparing 2026-02-13 vs 2025-02-14View on EDGAR →
FINANCIAL ANALYSIS

Bio-Rad's financial profile presents a stark contrast between operational struggles and underlying strength. Operating income collapsed substantially year-over-year, signaling major profitability challenges or significant non-recurring expenses. However, the company demonstrated financial resilience with operating cash flow growing 16.9% to $532.2M and total assets expanding 12.9% to $10.6B, while shareholders' equity increased 13.5% to $7.5B, suggesting the business fundamentals remain intact despite the earnings headwinds.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
-82.5%
$269.0M→$47.2M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Share Buybacks
Cash Flow
+45.1%
$203.6M→$295.5M

Share repurchases increased 45.1% — management returning capital, signals confidence in intrinsic value.

Operating Cash Flow
Cash Flow
+16.9%
$455.2M→$532.2M

Operating cash flow grew 16.9% — strong conversion of earnings to cash, healthy business fundamentals.

Stockholders Equity
Balance Sheet
+13.5%
$6.6B→$7.5B

Equity base grew 13.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+12.9%
$9.4B→$10.6B

Asset base grew 12.9% — expansion through organic growth, acquisitions, or capital deployment.

Total Liabilities
Balance Sheet
+11.7%
$2.8B→$3.1B

Liabilities increased 11.7% — monitor debt-to-equity ratio and interest coverage.

Current Liabilities
Balance Sheet
+10.5%
$467.8M→$517.0M

Current liabilities rose 10.5% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-02-13
PRIOR — 2025-02-14
ADDED
As of February 9, 2026, there were 21,924,284 shares of Class A Common Stock and 5,066,110 shares of Class B Common Stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 7A.
(referred to in this report as Bio-Rad, we, us, the Company, and our ) is a multinational life science and clinical diagnostics company that develops, manufactures, and markets a broad portfolio of instruments, systems, reagents, and consumables.
We have direct operations in over 36 countries outside the United States through subsidiaries focused on sales, customer service, and product distribution.
In certain locations outside and within these countries, our sales efforts are supplemented by distributors and agents.
+7 more — sign up free →
REMOVED
As of February 11, 2025, there were 22,940,805 shares of Class A Common Stock and 5,070,337 shares of Class B Common Stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 7A.
(referred to in this report as Bio-Rad, we, us, the Company and our ) is a multinational developer, manufacturer, and worldwide distributor of our own life science research and clinical diagnostics products.
Bio-Rad develops, manufactures, and supplies life science research, healthcare, analytical chemistry and other markets with a broad range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
We have direct distribution channels in over 36 countries outside the United States through subsidiaries whose focus is sales, customer service and product distribution.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →